Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025
Rhea-AI Summary
Champions Oncology (CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its fourth quarter and year-end financial results announcement for Wednesday, July 23, 2025, after market close.
The company will host a conference call at 4:30 P.M. EDT to discuss the results. Investors can join via phone using access code 792442 or listen to the replay within 72 hours through the company's website or by dialing with passcode 52754.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CSBR gained 0.25%, reflecting a mild positive market reaction. Argus tracked a trough of -8.5% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $283K to the company's valuation, bringing the market cap to $113M at that time.
Data tracked by StockTitan Argus on the day of publication.
HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter and year ended April 30, 2025, on Wednesday, July 23, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 792442. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 52754, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Champions Oncology (CSBR) release Q4 and year-end 2025 earnings?
How can investors join Champions Oncology's Q4 2025 earnings call?
Where can I find the replay of Champions Oncology's Q4 2025 earnings call?
What period will Champions Oncology's earnings report cover?
